Preclinical Murine Models for Lung Cancer: Clinical Trial Applications
Murine models for the study of lung cancer have historically been the backbone of preliminary preclinical data to support early human clinical trials. However, the availability of multiple experimental systems leads to debate concerning which model, if any, is best suited for a particular therapeuti...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2015-01-01
|
Series: | BioMed Research International |
Online Access: | http://dx.doi.org/10.1155/2015/621324 |
id |
doaj-31dbb60fdab744c2ba78a94aa11be728 |
---|---|
record_format |
Article |
spelling |
doaj-31dbb60fdab744c2ba78a94aa11be7282020-11-24T20:56:06ZengHindawi LimitedBioMed Research International2314-61332314-61412015-01-01201510.1155/2015/621324621324Preclinical Murine Models for Lung Cancer: Clinical Trial ApplicationsAmelia Kellar0Cay Egan1Don Morris2Departments of Oncology/Medicine, University of Calgary, 1331 29 Street NW, Calgary, AB, T2N 4N2, CanadaDepartments of Oncology/Medicine, University of Calgary, 1331 29 Street NW, Calgary, AB, T2N 4N2, CanadaDepartments of Oncology/Medicine, University of Calgary, 1331 29 Street NW, Calgary, AB, T2N 4N2, CanadaMurine models for the study of lung cancer have historically been the backbone of preliminary preclinical data to support early human clinical trials. However, the availability of multiple experimental systems leads to debate concerning which model, if any, is best suited for a particular therapeutic strategy. It is imperative that these models accurately predict clinical benefit of therapy. This review provides an overview of the current murine models used to study lung cancer and the advantages and limitations of each model, as well as a retrospective evaluation of the uses of each model with respect to accuracy in predicting clinical benefit of therapy. A better understanding of murine models and their uses, as well as their limitations may aid future research concerning the development and implementation of new targeted therapies and chemotherapeutic agents for lung cancer.http://dx.doi.org/10.1155/2015/621324 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Amelia Kellar Cay Egan Don Morris |
spellingShingle |
Amelia Kellar Cay Egan Don Morris Preclinical Murine Models for Lung Cancer: Clinical Trial Applications BioMed Research International |
author_facet |
Amelia Kellar Cay Egan Don Morris |
author_sort |
Amelia Kellar |
title |
Preclinical Murine Models for Lung Cancer: Clinical Trial Applications |
title_short |
Preclinical Murine Models for Lung Cancer: Clinical Trial Applications |
title_full |
Preclinical Murine Models for Lung Cancer: Clinical Trial Applications |
title_fullStr |
Preclinical Murine Models for Lung Cancer: Clinical Trial Applications |
title_full_unstemmed |
Preclinical Murine Models for Lung Cancer: Clinical Trial Applications |
title_sort |
preclinical murine models for lung cancer: clinical trial applications |
publisher |
Hindawi Limited |
series |
BioMed Research International |
issn |
2314-6133 2314-6141 |
publishDate |
2015-01-01 |
description |
Murine models for the study of lung cancer have historically been the backbone of preliminary preclinical data to support early human clinical trials. However, the availability of multiple experimental systems leads to debate concerning which model, if any, is best suited for a particular therapeutic strategy. It is imperative that these models accurately predict clinical benefit of therapy. This review provides an overview of the current murine models used to study lung cancer and the advantages and limitations of each model, as well as a retrospective evaluation of the uses of each model with respect to accuracy in predicting clinical benefit of therapy. A better understanding of murine models and their uses, as well as their limitations may aid future research concerning the development and implementation of new targeted therapies and chemotherapeutic agents for lung cancer. |
url |
http://dx.doi.org/10.1155/2015/621324 |
work_keys_str_mv |
AT ameliakellar preclinicalmurinemodelsforlungcancerclinicaltrialapplications AT cayegan preclinicalmurinemodelsforlungcancerclinicaltrialapplications AT donmorris preclinicalmurinemodelsforlungcancerclinicaltrialapplications |
_version_ |
1716790757645352960 |